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Abstract
Introduction: High-
quality randomised controlled
trials (RCTs) provide the most reliable evidence on
the comparative efficacy of new medicines. However,
non-
randomised studies (NRS) are increasingly
recognised as a source of insights into the real-
world performance of novel therapeutic products,
particularly when traditional RCTs are impractical or
lack generalisability. This means there is a growing
need for synthesising evidence from RCTs and NRS in
healthcare decision making, particularly given recent
developments such as innovative study designs,
digital technologies and linked databases across
countries. Crucially, however, no formal framework
exists to guide the integration of these data types.
Objectives and Methods: To address this gap, we
used a mixed methods approach (review of existing
guidance, methodological papers, Delphi survey)
to develop guidance for researchers and healthcare
decision-makers on when and how to best combine
evidence from NRS and RCTs to improve transparency
and build confidence in the resulting summary effect
estimates. Results: Our framework comprises seven
steps on guiding the integration and interpretation
of evidence from NRS and RCTs and we offer
recommendations on the most appropriate statistical
approaches based on three main analytical scenarios
in healthcare decision making (specifically, ‘high-
bar evidence’ when RCTs are the preferred source of
evidence, ‘medium,’ and ‘low’ when NRS is the main
source of inference). Conclusion: Our framework
augments existing guidance on assessing the
quality of NRS and their compatibility with RCTs for
evidence synthesis, while also highlighting potential
challenges in implementing it. This manuscript
received endorsement from the International Society
for Pharmacoepidemiology.

Introduction
Comparative effectiveness research is a key step
in the evaluation of novel therapeutic products.
Although randomised controlled clinical trials
(RCTs) are the established method for providing

information on the relative efficacy and safety
of health interventions, it may be impractical
to conduct them, and those available may be
sparse, small and potentially unrepresentative of
the patient populations or conditions found in
real-world settings. Consequently, evidence from
such studies alone might not reliably reflect how
medical interventions are likely to perform when
used in everyday clinical care.1–3 For this reason,
there has been a growing demand, especially
from regulatory bodies (Food and Drug Administration [FDA], European Medicines Agency
[EMA]) to incorporate real-world evidence (RWE)
from routine clinical practice as found in non-
randomised studies (NRS) to complement information from RCTs and potentially cover the ‘efficacy-
effectiveness’ gap.4–7 The regulatory acceptance of
RWE will present the challenge to other healthcare
decision-makers (payers, health technology assessment (HTA) bodies) to increasingly use NRS for
their policy decisions. Such evidence is potentially
available via healthcare claims databases, electronic health records (EHR), patient registries,8–10
and cohort and case–control studies, facilitated
by the emergence of digital technologies,9 and the
promotion of exchange of EHRs across countries.9
These changes have occurred in parallel with
increasing pressure from patient advocacy groups
to consider more patient-centred information in
health products value assessments.11

Need for guidance
The International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research
(CER) Special Interest Group (SIG) has previously
commented on the challenges of using RWE from
NRS in assessing comparative treatment effects. It
has also highlighted how recent methodological
advances can help to address inherent limitations
of NRS, such as selection and confounding.12
Recent publications have emphasised the need
for ongoing discussion among stakeholders about
when and how data from NRS can be used when
the ‘totality of evidence’ is considered for assessing
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guidance to fill in these knowledge gaps to ensure the validity of
non-RCT results.

What is already known about this subject?

Summary points of the framework

►► Non-randomised studies (NRS) are increasingly

recognised as being complementary to randomised
controlled trial evidence for making credible
estimates of the comparative treatment effects of
medical products.
►► The lack of methodological frameworks to
guide synthesis of results of NRS with those of
randomised clinical trials (RCTs) is a major cause of
the low uptake of cross-study design synthesis for
healthcare decision making and has been widely
recognised by different organisations.
►► "What can our framework offer"?
►► We propose a seven-step framework to
systematically identify evidence for NRS, critically
appraise and appropriately synthesise it with the
results from RCTs.
►► Our framework considers three main analytical
scenarios based on the evidence-generation
needs for a healthcare decision-making problem;
‘high-bar,’ ‘medium’ and ‘low’ depending on
whether evidence from randomised trials or
non-randomised studies is the main source for
trustworthy summary treatment effect estimates.
►► Our framework emphasizes that the effect estimates
from all the randomised and non-randomised
evidence should not directly be combined in a meta-
analysis without any type of statistical adjustment.
When cross-design synthesis is considered
appropriate, our framework guides researchers to
select the most relevant statistical technique for an
analytical scenario, such as using evidence from
non-randomised studies as priors, in three-level
hierarchical models and in bias-adjusted analysis.
Expert clinical opinion and statistical expertise is
required to avoid misleading results from combined
analysis of non-randomised and randomised
studies and increasing the risk of poorly informed
healthcare decisions with harmful consequences to
patients.
►► "How might this framework impact healthcare
decision-making in the future?"
►► This framework will ultimately facilitate decisions
around if, when and how evidence from NRS can
be combined along RCTs and produce reliable
treatment estimates applicable to a specific
targeted population relevant for healthcare
decision-making.

medical products, including complementing RCTs, to strengthen
evidence packages for novel treatments.13–15 However, there is
a lack of methodological guidance on selection, appraisal and
synthesis of evidence across different study designs in a consistent
and reproducible manner. Other researchers are working on
similar frameworks with a focus on specific conditions, such as
cancer.16 This methodological gap has been a key cause of the
scepticism of regulators and healthcare decision-makers towards
adopting novel methodologies proposed for the analysis of NRS.7
Our proposed, comprehensive framework provides much-needed
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This framework is intended for use when NRS is considered for
CER (or otherwise called relative effectiveness assessment in the
EU HTA context) to address limitations of RCTs for licensing applications for primary conditional or secondary approvals in other
indications, or to provide additional information for regulatory
or reimbursement decisions for existing (standard of care) treatments.17 For instance, the framework could be relevant for rare
diseases, in which conducting traditional RCTs may be impractical (eg, due to recruitment difficulties). It might also facilitate
assessment of real-world performance of products in patients with
multiple comorbidities or at longer time points.
For the purposes of the framework, NRS is defined as those
where the assignment of patients to a therapeutic product is not
determined by a trial protocol; where additional diagnostic or
monitoring procedures are not used or do not influence the care
patients receive but instead represent routine clinical practice.3 10
It is also assumed that NRS data can be collected either prospectively or retrospectively by observation in routine clinical practice, and can be analysed using epidemiological (biostatistical)
methods.

Framework aims and development
The goal for our framework (figure 1) is to enable the trustworthy generation of results from combining NRS and RCT data,
by providing specific recommendations on the appraisal tools of
study quality, how to select the most reliable NRS evidence for a
quantitative analysis with RCTs and various statistical approaches.
More specifically, it comprises seven steps, some of which are well-
established processes in evidence-based medicine (eg, systematic
search and identification of relevant evidence (steps 1 and 2)) and,
as such, are not described in full herein (readers should follow
the guidance by Cochrane,18 the Preferred Reporting Items for
Analyses (PRISMA) guidelines19
Systematic Reviews and Meta-
and the Strengthening the Reporting of Observational Studies in
Epidemiology Statement20). The goal is to provide specific recommendations for the critical appraisal of NRS (steps 3 and 4), for the
implementation of statistical approaches to combine the results
from NRS and RCTs (steps 5 and 6), and for facilitating a reliable
interpretation of pooled (meta-analysed) results (step 7). For that
reason, a mixed-
methods approach was adopted for retrieving
the most relevant literature and capitalising on the multidisciplinary experience of the working group on pharmacoepidemiology,
observational statistical analysis and healthcare decision making.
For step 3, we conducted a systematic literature review following
PRISMA guidelines and searching indexed databases (Embase,
PubMed) and general websites for tools that evaluated the validity
of NRS from inception to November 2019 (online supplemental
table 1) and online supplemental figures 1 and 23). In addition, a
Delphi survey among the ISPE CER SIG was conducted to identify the main critical elements that can threaten the validity of
NRS and developed the evaluation framework for assessing the
validity of existing tools (Supplementary figure 2). For steps 4–7,
we used a snowballing approach to perform reference checking
of relevant publications (already known to the working group)
from previous or ongoing RWE initiatives and key organisations
(such as the Innovative Medicines Initiative [IMI] GetReal, FDA
RWE Framework, Institute for Clinical and Economic Review
[ICER], EMA, Duke-Margolis Institute, HTA bodies, International
Society for Pharmacoeconomics and Outcomes Research ([ISPOR]/
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ISPE endorsed publications) and publications from selected journals (such as Clinical Pharmacology and Therapeutics, Research
Synthesis Method and Statistics in Medicine).

Steps of a systematic review combining NRS and RCTs
(1–4)
Step 1: defining the research question and identifying
systematically the evidence
The identification and synthesis of all available relevant evidence
(RCTs or NRS) in healthcare decision making must be done in
a systematic, reproducible and rigorous way to ensure unbiased
results regarding the effectiveness and safety of medical products.
Accordingly, we recommend that, before any quantitative analysis
comparing effects of different medical treatments is considered,
researchers and healthcare decision-makers should specify a clear
research question that defines the scope (‘conceptual step’21), the
Population, Intervention, Comparison, Outcomes, Study design
and Time (PICOST) criteria. The PICOST can be used to conduct a
scoping literature review and determine the need for summarising
evidence across RCTs and NRS. It is, for instance, possible that
published RCTs are scarce, or do not provide much information on
important outcomes (eg, when serious harms of a medical treatment are rare or do not occur during the RCT follow-up). This
decision may depend on both the frequency of an outcome but
also on its importance/weight for the decision making.18
When setting the PICOST criteria, it is advisable to search the
COMET database and record if a core outcome set is available for
the condition of interest. Additional searches, such as the Outcome
Measures Framework by the Agency for Healthcare Research and
Quality and recent movements by EU IMI2 initiatives (Big Data
for Better Outcomes) may facilitate the selection of standardised,
measurable real-world outcomes.
When defining the research question, reviewers should also
prespecify a list of ‘core’ confounders for which adjustment is
deemed necessary in NRS. ‘Core’ confounders are defined as
measured variables that influence treatment assignment, are
predictive of the outcome and remove confounding when adjusted
for. It is also helpful to identify, at this stage, (eg, intermediate or
collider) variables that should not be adjusted for in NRS. A practical approach for preselecting ‘core’ confounders is to leverage
prior knowledge of causal relationships for the specific decision
problem (eg, by constructing causal diagrams22) and/or eliciting
expert clinical opinion.

We advise readers to follow the detailed guidance by the
Cochrane Collaboration (chapter 24) on this topic and apply additional search strategies to overcome specific challenges associated with the identification of NRS (eg, insufficient indexing of
older NRS, large volume of evidence retrieved, additional time
and resources for searching, identification of multiple publications and avoidance of ‘duplicate’ data set analyses).23–25
Step 2: data extraction
This critical step of the framework will largely determine the availability of key information, and therefore, the selection of NRS
to be considered in the quantitative synthesis of evidence across
study designs (step 5 in the framework).26–28 Well-established data
collection processes such as using a predefined data extraction
template and dual extraction by two independent reviewers should
be followed.25 Incomplete data have been widely recognised as an
important challenge when NRS are used in CER. The ability to link
databases is a useful way to fill any data gaps but also to validate the data, therefore related datasets should be carefully cross
referenced and extracted.29–31 In general, reporting of information
for each NRS should follow the same principles as the extraction
of RCTs; information on study design, population, interventions,
types of analyses and summary treatment effect statistics (such
as extracting of treatment effect estimates using time-to event
models and avoiding binary outcomes)30–32 Additional data should
be extracted to facilitate the assessment of different type of biases
(eg, selection, attrition bias, outcome reporting bias). For instance,
it is recommended to extract a list of confounders considered for
the adjusted treatment effect analyses, or the method of propensity score adjustment.
With regard to extraction of summary effect estimates, when
adopting non-collapsible effect measures such as ORs or HRs, it is
important to distinguish between marginal (ie, population average
unadjusted) and conditional (ie, covariate-
adjusted) treatment
effects.33 34 Marginal effect measures greatly depend on the distribution of patient characteristics, and may vary even in the absence
of confounding.35 Previous research has shown that the difference
between marginal and conditional effects can be substantial, especially when the number of prognostic factors exceeds five, the OR
is above 1.25 (or smaller than 0.8), or the incidence proportion is
between 0.05 and 0.95.34 For this reason, pooling of marginal OR
or HR estimates in such situations is not recommended. Further,
when the marginal effect sizes are of primary interest, it may be
BMJ Evidence-Based Medicine Month 2020 | volume 0 | number 0 |
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Figure 1 International Society for Pharmacoepidemiology (ISPE) CER SIG framework for combining NRS with RCTs. CER, comparative effectiveness
research; NRS, non-randomised studies; RCT, randomised controlled trial; SIG, Special Interest Group.
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►► Methods for selecting participants (sampling

strategies to correct selection bias, inclusion and
exclusion criteria of target population, depletion of
susceptibles, external validity of target population).
►► Definition and measurement of exposure, outcomes,
covariates and follow-up.
►► Methods to address specific sources of bias through
study design (new user design, active comparator
design, methods to correct for immortal time bias
or time-window bias, detection or surveillance
bias, lost to follow-up bias, non-contemporaneous
comparator bias, reverse causation,
misclassification bias).
►► Confounding (study design to minimise
confounding, key confounders measured
and included in statistical analysis, potential
unmeasured confounding addressed in the analysis
(please see online supplemental figure 4) for a
summary of methods to adjust for either known or
unknown confounding).
►► Lack of appropriateness of statistical analyses
(with specific mention of overadjustment, and/or
incorrect outcome model specification).
►► Methods for assessing statistical uncertainty in the
findings.
►► Methods for assessing internal validity (eg,
sensitivity analysis addressing potential
confounding, measurement error or other biases).
►► Methods for assessing external validity (eg, post
hoc subgroup analysis, validation of results with
other similar population).

helpful to distinguish between the average treatment effect in the
entire targeted population and the average treatment effect on
the treated group in the study. These estimands target different
populations or subgroups within the same population, and therefore can yield different treatment estimates.36 The relevance of
(differences in) estimands is further discussed in steps 5–7. Finally,
estimates that are not directly available from the publication can
sometimes be derived from other reported information.30–32
Step 3: critical appraisal of available data sources
Following previous guidance,37 38 the group strongly recommends
that both RCTs and NRS should rigorously be assessed for their
validity and credibility before any cross-design synthesis can be
considered. Results from the Delphi survey which was conducted
as part of this framework development identified the following
methodological challenges most associated with NRS (box 1).
Although tools for critical appraisal are widely available,39 40
they vary considerably in their content (quality topics covered).
The choice of appraisal tool is therefore a concern, as it may
affect the selection of NRS for quantitative analysis and credibility of subsequent meta-analysis results. We recently conducted
a systematic review to evaluate existing tools for critical appraisal
of NRS and found that most of these cover the critical quality
domains (box 1). Unfortunately, items to identify some fatal methodological flaws (eg, inability to conduct a study using new-user
design or active comparator design, immortal time bias, depletion
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of susceptibles, reverse causation), and assessing issues around
the internal and external validity of NRS results are currently
missing in most of the existing tools. Based on our findings, we
recommend ROBINS-I and GRACE as these tools cover most issues
that are commonly encountered in NRS. However, it is advised
to perform a supplementary assessment on the domains not fully
covered by these tools (online supplemental figure 3). Tools for
assessing RCTs have been reviewed previously and the use of
Cochrane Risk of Bias tool is recommended,41 as use of this is
already an established practice in assessing the quality of RCTs.
Step 4: other issues to consider: small-study effects and
publication bias
Critical appraisal tools may help to discover important limitations
of NRS and RCTs but are not sufficient to identify all potential
sources of bias in a quantitative synthesis. Researchers should
also be alert to the possibility and implication of small-
study
effects for both RCTs and NRS. Small-study effects refers to the
generic phenomenon that smaller studies show different, possibly
larger, treatment effects than large studies; this may reflect that,
there is a higher chance for a small study with positive results
(strong treatment effect) to be published compared with a study
of a similar size but with negative results (publication bias)42 or
when small studies are of low quality (eg, when at increased risk
of outcome selection or reporting bias or due to increased clinical
heterogeneity).43 It is likely that the susceptibility to small-study
effects differs between RCTs and NRS in line with differences in
the standards that typically govern their design, conduct and
reporting; for example, NRS may be potentially at a higher risk of
publication bias compared with RCTs. However, these differences
may become less of an issue given the recent efforts to improve
the design and reporting of NRS. Since small-study effects may
affect the validity of meta-analysis results (especially if random-
effects model is applied), an evaluation is recommended to determine whether study results are associated with the size of the
study. This should be done separately for RCTs and for NRS,
and if possible, also separately for different types of NRS. This
assessment can, for example, be based on a funnel plots of study
results.44 Unfortunately, statistical tests for analysing funnel plots
suffer from low power and cannot determine definitively whether
meta-analysis results are invalid.45 46 Accordingly, their use is best
limited to exploring (rather than trying to confirm) any concerns
about publication bias.

Steps of a quantitative analysis of effect estimates
across study designs (5–7)
Meta-
analysis, the statistical technique to combine the study
results into a weighted average, while accounting for the precision of each study estimate, is widely being employed by decisionmakers to quantitatively synthesise evidence from multiple
sources (‘totality of evidence approach’) and produce comparative estimates of effects for the new technology under assessment
compared with standard clinical care. Researchers and healthcare decision-makers should consider the following underlying
concerns about NRS before combining results from such studies
with RCT data in evidence synthesis:
►► NRS are more prone to selection and confounding biases than
RCTs.
►► Estimands defined in RCTs are not necessarily transferrable
towards NRS and vice versa. It is, therefore, important to
consider the applicability of study results with respect to the
review question.
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Box 1 Methodological challenges to be addressed
by quality tools for non-randomised studies
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►►

►►
►►

►►

Evidence generation needs in healthcare decision setting and use of non-randomised studies (NRS) with randomised controlled trials (RCTs).

Special consideration needs to be paid in selecting the appropriate techniques for dealing with incorrect or missing values
(including outcomes).
Analyses that weight studies by simple quality scores should
be avoided.
Summary effect estimates of treatments that are based on
data from RCTs and NRS, may be biased and imprecise, even
after applying the recommended statistical methodology. Further sensitivity analyses are always recommended to explore
the impact of modelling assumptions.
When RCTs and NRS are combined through network meta-
analysis, there is a need for deeper investigation of ‘transitivity’ (ie, no systematic differences between the available treatment comparisons other than the treatments being compared
in the analysis) than when only RCTs are included.

Step 5: selecting the most relevant analytical scenario
The critical appraisal tools cited in step 3 along the other critical
domains identified by this group which are not covered by the
existing tools may help identify which NRS have enough validity
to be considered for evidence synthesis along RCTs. However,
given that these tools primarily aim to assess the internal validity
of studies, researchers are urged to also consider issues around
external validity (generalisability or applicability) in relation to
the PICOST criteria set up for the specific research question under

assessment. It is not advisable to use NRS which are assessed
at critical risk of bias (step 3) for combined analysis with RCTs
analysed results.
to avoid misleading and untrustworthy meta-
This approach differs from that recommended in RCTs meta-
analyses, where low-quality studies are usually only excluded in
a sensitivity analysis. Depending on the context of the review,
the research question and the contribution of NRS in the healthcare decision making problem (eg, if the product is for primary
or secondary approval), it may be necessary to perform a critical
appraisal separately for each outcome. For example, the presence of selection bias may be less relevant when assessing safety
outcomes as compared with effectiveness outcomes.
We consider below three analytical scenarios that may generate
new evidence and various examples of weighting between new
(RCT) and prior (NRS) evidence for an effectiveness labelling
change or an assessment of new products (figures 2 and 3). The
selection of the most applicable scenario for a given healthcare
decision problem will depend on the (1) clinical context (‘relevance or applicability’), (2) completeness of RCT data (‘evidence
gaps’) and (3) the magnitude and direction of possible biases of
NRS (‘data rigour or quality’). These scenarios are linked with the
hypothetical examples of the types of studies (RCTs, NRS) that
may be primarily considered for regulatory decision- making as
detailed in the white paper by Duke Margolis Center for Health
Policy.17 The corresponding methods outlined in this framework

Figure 3 A seven-sStep decision algorithm for the synthesis of non-randomised studies (NRS) and randomised controlled trials (RCTs) in healthcare
decision-making (ISPE CER SIG framework). CER, comparative effectiveness research; ISPE, International Society for Pharmacoepidemiology; PICOST,
Population, Intervention, Comparison, Outcomes, Study design and Time; SIG, Special Interest Group.
BMJ Evidence-Based Medicine Month 2020 | volume 0 | number 0 |
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Scenario 1: high-evidence bar situation
RCTs are generally considered the gold standard for generating
evidence about the efficacy of medical interventions as they are
designed to test treatment effects while essentially balancing
for all other factors (known and unknown) that may affect their
response to treatment. For some decision making problems, such
as a new product likely to significantly increase drug spending
or a product label expansion supporting a superiority claim, the
evidence generation needs are high and RCTs are the preferred
source of estimating comparative treatment effect estimates.
However, in some circumstances described previously, there may
still be a desire to augment the evidence from RCTs with results
from NRS without directly performing cross-study design meta-
analysis. This strategy may be instrumental when RCT evidence
is very imprecise (eg, results are only reported for surrogate
outcomes), not reflective of the patient population of interest or
not covering important patient groups, even when the evidentiary
needs for the decision problem are high.
In this circumstance, a natural approach is to treat the NRS
data as prior evidence for the RCT analyses, adopting a Bayesian
estimation framework.54 55 Here, the NRS data are summarised
using a (network) meta-analysis and, if necessary, adjusted for a
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predefined amount of bias. The bias adjustment can be performed
in different ways depending on the source of bias and the granularity of available data. For instance, it is possible to directly
adjust for (differences in) measurement error or missing data
with imputation methods. Alternatively, it is possible to apply
corrections to the study results by eliciting expert opinion or
using the credibility ceiling correction. The latter approach (credibility ceiling correction) assumes that no single NRS can provide
a maximum credibility ceiling above a certain percentage.56 The
results of the NRS analysis are then used as the prior distribution
for the (network) meta-analysis of the RCT data. In other words,
this approach will ‘pull’ the treatment-effect estimates from the
RCTs toward the (adjusted) summary effects from the NRS. By
default, the prior distribution(s) has the precision of the summary
effect estimate(s) from the NRS. However, it is possible to decrease
the precision of the prior distribution(s) by considering additional
sources of uncertainty, such as the presence of between-study
heterogeneity in the NRS results. A sensitivity analysis should also
be conducted to adjust each NRS in the meta-analysis for various
ceiling percentages and to observe the direction of effects and
consistency in the conclusions obtained (step 6).
Scenario 2: medium-evidence bar situation
In some circumstances, NRS are likely to provide additional
(complementary) information about the effectiveness and safety
of medical interventions, but their results cannot be directly used
as prior information for the RCT results. This situation may arise
when RCTs only provide evidence on short-
term or surrogate
endpoints (eg, when RCTs have low applicability),57 or when an
approved product is being tested in another (beyond its marketing
authorisation) indication. Treatment effects are then likely to
differ between the RCTs and the NRS, such that greater efforts
are needed to disentangle the potential sources of between-study
design heterogeneity.
A simple solution is to consider the use of three-level hierarchical models.54 55 These regression-based models use the first
level to model variation within individual studies, the second
level to model variation between studies, and the third level to
model variation between RCTs and NRS.58 They typically assume
that the treatment effects are different, but exchangeable, across
different types of studies, and allow for differences in between-
study heterogeneity within randomised and non-randomised data
sources.
Like traditional meta-
analysis methods, summary estimates
of treatment effects generated by three-level hierarchical models
represent a weighted average of the included studies. However, the
meta-analysis now yields a summary of treatment effect for each
distinct study design and an overall treatment effect across all
study designs. The overall treatment effect is then pulled towards
the results from large, homogeneous studies that share a common
design. In addition, because the contribution of each study is
adjusted for its study design, estimates of precision are likely to
better reflect the various sources of uncertainty (due to bias or
heterogeneity).
Scenario 3: low-evidence bar situation
In some situations, NRS may be the most reliable source of inference for obtaining and assessing the external validity of comparative effect estimates. It is, for instance, possible that published
RCTs are scarce, or have very poor quality. It is also possible that
results from RCTs have limited external validity or applicability
about the research question, for instance in postmarketing settings
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are based on generalised linear mixed models and can be used
to summarise many types of association (eg, HR, OR and change
score). A critical consideration for each of these scenarios is the
attempt to quantify bias in NRS. A helpful review of methods and
results from previous studies comparing (and sometimes meta-
analysing) RCTs with NRS is provided in the HTA No. 21.7 by
the UK National Institute for Health and Research online supplemental appendix 2.47
For studies assessed as ‘unclear risk of bias’, their a priori
exclusion from further analyses with RCTs is not recommended.
However, for scenarios 2 and 3, their inclusion may directly affect
the pooled treatment effect estimates (in comparison to scenario
1) and should therefore only be explored in a sensitivity analysis. More specifically, any bias concerns about treatment effects
estimates should be explored at a later step using predesigned
sensitivity analyses.
Before any cross-design synthesis of RCTs and NRS is considered, the direction of treatment effects between study designs
should be investigated and assessed if it differs substantially
(eg, evidence from NRS suggests no effect whereas good-quality
RCTs suggest a strong effect). Several reviews have found little
difference between the evidence from observational studies and
RCTs,48–50 but counterexamples exist.51
Furthermore, it is important that appropriate statistical models
are applied to combine comparative treatment effects from NRS
and RCTs, as studies will often differ with respect to their validity
(risk of bias) and applicability.52 It is rarely justifiable to directly
combine the effect estimates from all the randomised and non-
randomised evidence in a meta-analysis without any type of cross-
design statistical adjustment.53 54 In many situations, the observed
differences between the results from RCTs and NRS are prone to
much uncertainty. It is therefore recommended to adopt analytical methods that distinguish between the two data sources (RCTs
and NRS) and allow for some bias corrections (when this discrepancy cannot be explained by differences in study design and
selection of populations). The implementation of these methods
is not straightforward and will often require advanced statistical
support. A description of approaches for combining RCTs with
NRS has been presented as part of the GetReal WorkPackage 4 and
is summarised in online supplemental table 2.

General medicine

Step 6: quantifying and examining statistical heterogeneity
As previously mentioned, it will often be difficult to avoid statistical heterogeneity in a meta-analysis especially when NRS are
included. These studies are often prone to residual confounding and
may therefore affect pooled estimates of relative treatment effects
even when excluding studies at high risk of bias and/or adopting
advanced meta-analysis methods. Therefore, exploring differences
between RCTs and NRS results in a meta-analysis is an important
step in evidence synthesis.73–76 This can be achieved by adopting
random effects models and quantifying the presence of between-
study heterogeneity. In practice, when substantial between-study
heterogeneity is present, the ‘average’ effect may no longer be
an appropriate summary estimate. Between-study heterogeneity
typically occurs when there are interactions between the treatment effect and the study or a study-level variable, or when the

treatment effect varies across patients.77 To assist the interpretation of between-study heterogeneity, researchers may derive τ2 or
I2 statistics although these metrics have limited clinical interpretation, especially when used in isolation. More relevant for healthcare decision making is the construction of (approximate) prediction intervals. Prediction interval depict the expected range of true
effects in future studies if those settings are similar to the settings
included in the meta-analysis (please see further details on how
to calculate a prediction interval in the publication by Riley et
al78) which offer advantages in examining whether the variation
of effect estimates is attributable to between-
study heterogeneity and enabling the decision makers to interpret the impact of
heterogeneity in relation to harm and clinical benefit thresholds
(commonly used by decision-makers).78 79 Meta-regression might
be also a way of exploring potential sources of between-study
heterogeneity, such as the presence of publication bias, differences
in study design or differences in the control treatment.80 However,
this approach has very low power and is prone to ecological bias
when used to investigate summarised participant-level characteristics (eg, mean age) as modifier of treatment effect. Several
authors have, therefore, recommended the retrieval and inclusion
of individual-participant data,81 a topic beyond the scope of this
manuscript.
Finally, in all analytical scenarios, as previously noted,
prespecified sensitivity analyses should be performed to assess the
extent to which the cross-synthesis results from NRS and RCTs are
credible and, understanding the impact of assumptions made in
the selection and analysis of NRS by omitting individual studies
(eg, in terms of NRS study design, study quality, outcomes time
points or other statistical methods employed) on the treatment
effects. These sensitivity analyses should focus on key issues that
may potentially introduce uncertainty in the estimates of effects
(even though it might be, in some cases, difficult to quantify) and
lower the credibility of NRS in the decision making.
Step 7: interpretation of effect estimates
Aiming towards increasing the credibility of treatment effects
estimates by inclusion of NRS, the interpretation of the results
of any quantitative synthesis of NRS and RCTs should always
consider the following three points: (1) the quality of the included
studies (both RCTs and NRS), (2) the robustness of adopted analytical methods and (3) the results of any sensitivity analyses. Since
random-effects summary estimates may be of limited value in
the presence of substantial heterogeneity, prediction intervals
may help to explore their potential impact on decision making
(although it can only be calculated when the meta-
analysis
includes at least three studies and is most appropriate when the
studies have low risk of bias).78 This group discussed how this
step of the framework is heavily dependent on the methods, and
the context stipulated different regulatory, payer or reimbursement bodies and the level of certainty/confidence in results they
set as thresholds in their decision making.82 For example, there
may be a preference for certain types of evidence (including RCT
and NRS) to support economic arguments in the postregulatory
environment. Furthermore, when a health economic analysis for
new medical technologies is required in the technology’s assessment, a probabilistic scenario analysis of economic modelling can
provide different thresholds of ‘trust’ in the results generated by
combining NRS and RCT data. However, for organisations that
only assess the clinical effects of new products, more scrutiny may
be placed on the selection of the most appropriate comparative
analytical approach and the consistency of results between NRS
and RCTs.
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where the focus is on safety and long-term outcomes. Although
corresponding pooled results can be summarised using traditional
random-effects meta-analysis methods, researchers should always
evaluate the impact of potential bias(es) arising from the synthesis
of individual NRS alone or in combination with RCTs.59 Methods
to record and assess the types of bias(es) at the NRS (study) level
have already been captured under steps 2 and 3.
While developing this framework, the application of several
methods was reviewed. These methods have been developed for
adjusting for bias in a meta-analysis of NRS and RCTs which may
be applicable to different healthcare decision making problems,
depending on the specific biases associated with the NRS under
consideration. These methodological approaches may adjust the
meta-analysis model to account for bias parameters (eg, for ascertainment or disease onset misclassification bias,60–63 misclassification of exposure or outcome,64 or uncontrolled confounding).65
The application of bias adjustments has been widely advocated
in the estimation of treatment effects by NRS and should also
be considered during their meta-
analysis.66–69 For healthcare
decision-makers, quantifying bias is a critical step, for instance,
through clinician and patient surveys or consensus meetings.67
This method proposes to construct an idealised study (where all
questions can be answered) and ask assessors to elicit the likely
magnitude and variance of various types of biases including
both internal and external validity bias.70 Expert elicitation is
a complex task, because the magnitude of bias always remains
uncertain and quantifying the level of uncertainty is part of the
elicitation process. Estimates of bias(es) can then be used to adjust
the extracted treatmente ffect estimates, and/or to decrease the
precision of NRS results accounting for both the magnitude and
the uncertainty of the potential bias(es). The adjusted estimates
can then be pooled using traditional (network) meta-
analysis
methods—an approach known as a design-
adjusted analysis.55
This method, which aims to reduce decision uncertainty, is widely
used in HTAs, particularly for economic modelling.70
Alternatively, it is possible to perform data-driven bias adjustments in evidence synthesis. Several methods have been proposed
for integrating bias modelling in the meta-analysis, and these
commonly assume that (some of) the NRS overestimate the true
treatment effect.58 A recent approach called hierarchical meta-
regression (HMR) distinguishes between biased and unbiased study
results and derives the risk of bias automatically from observed
study design features (eg, the results from an appraisal of study’s
quality71 72). A mixture model is then used to convert the observed
treatment-effect estimate into an unbiased effect. Thus, HMR can
identify studies presenting conflicting evidence and downplay
their contribution in the (network) meta-analysis.

General medicine

Recent developments in the NRS landscape and the lack of trust
among stakeholders in the wider application of such evidence in
healthcare decision making have highlighted the pressing need
for methodological standards in this area. In particular, this
requires widespread understanding of, and familiarity with, the
methodological and analytical approaches of NRS that are most
likely to offer decision making bodies the level of scientific rigour
and certainty they require to rely on evidence from NRS when
combined with RCTs. There must also be a recognition of key
challenges in the use and interpretation of NRS in this setting
and the fact that these will vary with the specific methodological or clinical issues to the decision problem under consideration.
Advanced statistical support may be required to undertake some
of the proposed analyses of combined analyses of RCTs and NRS.
Against this background, our proposed framework aims to set up
clear guidance for considering evidence across different study
designs—specifically RCTs and NRS—and ensure appropriate, well-
established approaches are followed in combining evidence from
these sources. We believe it will improve transparency and build
confidence in the use of NRS effect estimates and will prompt
discussion among regulators and healthcare decision makers who
may be sceptical toward the standardised adoption of these novel
methodologies (previously described as the ‘methodology aversion
in drug regulation’).83 The timing of this framework development
is also highly relevant, given that many decision making frameworks are currently undergoing revisions to acknowledge and
identify ways to incorporate the potential value of NRS in their
assessments. However, persistent issues related to poorly reported
publications, data inaccessibility from RWE repositories and data
governance (which were beyond the scope of this framework) are
critical to overcome in order for industry, healthcare bodies and
decision makers to explore the added value of NRS and test the
application of the proposed methods for our framework. A mandatory national registry for NRS along with strict protocols in analysis and reporting of data (as previously recommended by ISPOR/
ISPE taskforce) would provide a platform to further increase the
credibility of evidence from NRS.
Therefore, readers are encouraged to consider these recommendations alongside previous guidance related to the design of NRS
such as study registration (particularly for hypothesis-evaluating
treatment effectiveness studies), data collection (primary or
secondary), source validation and results reproducibility, topics
not covered by our framework.45 53 67 84–88 In the future, expanding
this framework by considering analyses involving reweighting
RCT evidence with real-world NRS evidence89 or using individual
patient data or syntheses of RCT and NRS to inform the design
of subsequent RCTs in a clinical development programme90 could
provide greater clarity in other healthcare situations. Further
research on analytical methods that may reduce areas of uncertainty in estimating treatment effects from NRS (such as estimating the degree of error in the estimates, investigating the role
of machine learning for improving confounder adjustment in
EHRs) is much needed.
The next phase of this framework will be testing and validating
the proposed recommendations using case studies from NRS and
RCTs in a specific healthcare decision problem and disseminating
the findings to a wider audience. This validation stage should
provide additional insights into the utility of the framework in
a real-world healthcare decision-making setting and, therefore,
could be updated with new methodologies and help to build
trust in its reproducibility. We hope that our framework may also
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guide researchers to appropriately design and primarily analyse
evidence from NRS (accounting for different types of biases) to
meet the high standards rightly expected by healthcare decision-
makers and highly deserved by patients.
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